Genzyme: Lemtrada Now Available In U.S. - Quick Facts

(RTTNews) - Genzyme, a Sanofi company, (SNY) announced that the first U.S. patients have initiated treatment with Lemtrada (alemtuzumab) in the commercial setting following its November 14th FDA approval for the treatment of patients with relapsing forms of multiple sclerosis.

Lemtrada is only available through a restricted distribution program, the Lemtrada REMS. The company said the program has been developed to ensure that access to Lemtrada in the U.S. is only through certified prescribers, healthcare facilities and pharmacies and to also ensure that patients are enrolled in the REMS program.

Lemtrada has a unique dosing and administration schedule of two annual treatment courses. The first treatment course is administered via intravenous infusion on five consecutive days, and the second course is administered on three consecutive days, 12 months later.